Probiotics for the treatment of hyperlipidemia: Focus on gut-liver axis and lipid metabolism
Pharmacological Research,
Год журнала:
2025,
Номер
214, С. 107694 - 107694
Опубликована: Март 10, 2025
Язык: Английский
Alleviating effect of Lactobacillus fermentum E15 on hyperlipidemia and hepatic lipid metabolism in zebrafish fed by a high-fat diet through the production of short-chain fatty acids
Frontiers in Nutrition,
Год журнала:
2025,
Номер
12
Опубликована: Март 3, 2025
Introduction
Hyperlipidemia
is
regarded
as
one
of
the
crucial
factors
leading
to
atherosclerosis
and
other
cardiovascular
diseases.
Gut
microbiota
plays
an
important
role
in
regulating
host
lipid
metabolism.
Nevertheless,
exact
mechanisms
behind
this
remain
unclear.
Methods
In
present
study,
a
hyperlipidemic
zebrafish
model
was
established
using
high-cholesterol
diet
(HCD)
evaluate
anti-hyperlipidemic
effects
Lactobacillus
fermentum
E15
(
L.
E15).
Results
showed
that
effectively
reduced
accumulation
blood
vessels
liver
HCD-fed
larvae.
Meanwhile,
improved
abnormal
levels,
normalized
enzyme
activity.
Real-time
quantitative
polymerase
chain
reaction
(RT-qPCR)
analysis
revealed
downregulated
expression
sterol
regulatory
element-binding
factor
(SREBP-1),
peroxisome
proliferator-activated
receptor-gamma
(PPAR-
γ
),
fatty
acid
synthase
(Fasn),
while
upregulated
receptor-alpha
α
).
Additionally,
metabolomic
produced
series
short-chain
acids
(SCFAs),
including
acetic
acid,
propionic
butyric
isovaleric
acid.
Notably,
contributed
reduction
droplet
contrast,
blocking
G-protein
coupled
receptor
43
(GPR43)
with
pertussis
toxin
(PTX)
abolished
on
reducing
RT-qPCR
results
further
suggested
both
promoted
GPR43
leptin
A,
which
inhibited
by
PTX.
Conclusion
These
findings
alleviates
HCD-induced
hyperlipidemia
activating
through
SCFAs.
Язык: Английский
Updated Insights into Probiotic Interventions for Metabolic Syndrome: Mechanisms and Evidence
Probiotics and Antimicrobial Proteins,
Год журнала:
2025,
Номер
unknown
Опубликована: Май 7, 2025
Язык: Английский
Impact of Gut Microbiome Interventions on Glucose and Lipid Metabolism in Metabolic Diseases: A Systematic Review and Meta-Analysis
Life,
Год журнала:
2024,
Номер
14(11), С. 1485 - 1485
Опубликована: Ноя. 14, 2024
Background:
The
gut
microbiome
is
increasingly
recognized
as
a
key
player
in
metabolic
health,
influencing
glucose
and
lipid
metabolism
through
various
mechanisms.
However,
the
efficacy
of
microbiota-targeted
interventions,
such
probiotics,
prebiotics,
fecal
microbiota
transplantation
(FMT),
diet-based
treatments,
remains
unclear
for
specific
outcomes.
In
this
study,
aim
was
to
evaluate
impact
these
interventions
on
parameters
individuals
with
diseases
diabetes
mellitus
(DM),
obesity,
syndrome.
Methods:
This
systematic
review
meta-analysis
included
41
randomized
controlled
trials
that
investigated
effects
treatments
fasting
glucose,
glycated
hemoglobin
(HbA1c),
homeostatic
model
assessment
insulin
resistance
(HOMA-IR),
total
cholesterol,
low-density
lipoprotein
cholesterol
(LDL-C),
high-density
(HDL-C),
triglycerides.
A
comprehensive
search
conducted
using
databases
like
PubMed,
Google
Scholar,
Scopus,
focusing
targeting
microbiota.
performed
random-effects
models,
effect
sizes
calculated
each
outcome.
Risk
bias
assessed
Cochrane
Bias
tool.
Results:
Gut
significantly
reduced
HbA1c,
HOMA-IR,
LDL-C,
triglycerides,
moderate
heterogeneity
observed
across
studies.
also
led
modest
increases
HDL-C
levels.
Probiotic
synbiotic
showed
most
consistent
benefits
improving
both
profiles,
while
FMT
yielded
mixed
results.
Short-term
rapid
microbial
shifts
but
less
pronounced
improvements,
whereas
longer-term
had
more
substantial
benefits.
Conclusions:
it
demonstrated
can
improve
outcomes,
offering
potential
therapeutic
strategy
managing
diseases.
effectiveness
varies
depending
type,
duration,
population
characteristics,
highlighting
need
further
long-term
studies
assess
sustained
modulation
health.
Язык: Английский